2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122028
    HSD-016 946396-92-5 99.95%
    HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research.
    HSD-016
  • HY-122052
    UK‑396082 400044-47-5 99.89%
    UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD).
    UK‑396082
  • HY-122210
    T521 891020-54-5 99.73%
    T521 is an inhibitor of E3 ligase. T521 can be used in cancer and metabolic disease related research.
    T521
  • HY-122439
    Lovastatin acid 75225-51-3 98%
    Lovastatin acid (Mevinolinic acid; MSD803), an active metabolite of Lovastatin (HY-N0504), is a potent competitive HMG-CoA reductase inhibitor with a Ki of 0.6 nM. Lovastatin acid acts as a competitive inhibitor with respect to substrate HMG-CoA, interfering cholesterol synthesis. Lovastatin acid can be used for the research of hypercholesterolemia.
    Lovastatin acid
  • HY-123033
    Nicotinamide riboside 1341-23-7 98%
    Nicotinamide riboside, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
    Nicotinamide riboside
  • HY-123039
    CP-532623 261947-38-0 ≥99.0%
    CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties.
    CP-532623
  • HY-124064
    TMP-153 128831-46-9 99.34%
    TMP-153 is an orally active inhibitor of ACAT with an IC50 value of approximately 5-10 nM against hepatic and intestinal ACAT in varicose animals. TMP-153 exhibits cholesterol-lowering effects and can be utilized in the research of atherosclerosis.
    TMP-153
  • HY-124073
    Dihydrocapsiate 205687-03-2 99.33%
    Dihydrocapsiate, as a compound of capsinoid family, is an orally active TRPV1 agonist. Dihydrocapsiate can be used for the research of metabolism disease.
    Dihydrocapsiate
  • HY-124230
    15-PGDH-IN-3 355827-05-3 98%
    15-PGDH-IN-3 (Compound 61) is a selective competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
    15-PGDH-IN-3
  • HY-124735
    RH01687 302901-13-9 99.85%
    RH01687 is a compound that can protect pancreatic β cells against endoplasmic reticulum stress-induced cell death. RH01687 has the potential for the research of diabetes.
    RH01687
  • HY-124771
    RH01386 301177-36-6 99.76%
    RH01386 is a small molecule that can prevent endoplasmic reticulum stress (ERS)-induced β cell dysfunction and death, and inhibits proapoptotic gene expression. RH01386 restores ERS-impaired glucose-stimulated insulin secretion responses. RH01386 has the potential for type 2 diabetes treatment.
    RH01386
  • HY-124857
    7DG 26927-01-5 98%
    7DG (7-Desacetoxy-6,7-dehydrogedunin) is a PKR inhibitor, P2X7 purinergic receptor inhibitor, and skin-lightening agent. 7DG binds outside the ATP-catalytic domain of PKR, blocks the kinase activity-independent protein-protein interactions of PKR, inhibits the phosphorylation and activity of PKR, disrupts ASC assembly and caspase-1 activation, and suppresses the activation of the NLRP1 inflammasome. 7DG inhibits pyroptosis, suppresses the ATP-P2X7 signaling pathway, and abolishes ATP-induced increases in the expression levels of MITF, tyrosinase, PMEL/gp100, and melanin content. 7DG exerts skin-lightening effects in cultured skin in vitro. 7DG can be used in research related to chronic obstructive pulmonary disease, gout, type 2 diabetes, Alzheimer's disease, and hyperpigmentary skin disorders.
    7DG
  • HY-124958
    NDMC101 1308631-40-4 99.91%
    NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.
    NDMC101
  • HY-125025
    SMI 6860766 433234-16-3 98%
    SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation.
    SMI 6860766
  • HY-125096
    C108297 864972-30-5 99.97%
    C108297 is a selective glucocorticoid receptor (GR) modulator (GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM). C108297 attenuates obesity by reducing caloric intake and increasing lipolysis and fat oxidation, and in addition attenuates inflammation.
    C108297
  • HY-125319
    Amidepsine A 169181-28-6 98.38%
    Amidepsine A is a fungal metabolite isolated from the culture broth of Humicola sp. FO-2942 that inhibits Diacylglycerol acyltransferases (DGAT) activity.
    Amidepsine A
  • HY-125826
    Heptasaccharide Glc4Xyl3 121591-98-8 98.0%
    Heptasaccharide Glc4Xyl3, a covalent inhibitor of endo-xyloglucanases, is used for the identification and analysis of diverse xyloglucan-active enzymes in nature[1].
    Heptasaccharide Glc4Xyl3
  • HY-126233
    PAT-347 1689554-51-5 98.63%
    PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood.
    PAT-347
  • HY-126738
    Anacardic acid triene 103904-73-0 98.51%
    Anacardic acid triene is an ester product.
    Anacardic acid triene
  • HY-128029
    Glycogen phosphorylase-IN-1 648926-15-2 98.15%
    Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes.
    Glycogen phosphorylase-IN-1
Cat. No. Product Name / Synonyms Application Reactivity